Last updated: January 17, 2026
Executive Summary
Patent JP2024037994, titled "Method and Apparatus for Targeted Drug Delivery," filed by PharmaTech Inc. in April 2024, embodies a novel approach to precision pharmaceutical administration. This document delves into the patent’s scope, claims, legal standing, and the broader patent landscape within Japan’s biopharmaceutical sector, providing insights critical to stakeholders in pharmaceutical innovation, licensing, and competitive strategy. The analysis reveals a broad scope targeting nanoparticle-mediated drug targeting, with claims encompassing both the delivery method and apparatus, positioning it as a potentially influential patent in targeted therapeutics.
Summary Overview
| Aspect |
Details |
| Patent Number |
JP2024037994 |
| Filing Date |
April 16, 2024 |
| Publication Date |
October 21, 2024 |
| Applicant |
PharmaTech Inc., Japan |
| Priority Date |
Not explicitly specified but likely April 16, 2024 |
| Patent Term |
20 years from filing (if granted) |
| Patent Classifications |
IPC: A61K 31/4012 (drug delivery), B29C 70/00 (nanoparticle manufacturing), C12N 15/86 (gene and cell therapy) |
What Is the Scope of JP2024037994?
Core Technology
The patent claims to provide a "targeted drug delivery system utilizing biocompatible nanoparticles conjugated with specific ligands targeting disease biomarkers." It addresses the challenges of conventional systemic drug delivery by enhancing specificity and reducing systemic toxicity.
Principal Features
- Nanoparticle Composition: Biodegradable, customizable in size (50-200 nm), surface-modified for stability.
- Targeting Ligands: Antibodies, peptides, or small molecules designed to bind selectively to disease-associated biomarkers (e.g., tumor antigens).
- Delivery Method: Routes include intravenous and localized injection, facilitating targeted accumulation.
- Device Apparatus: An automated delivery device capable of real-time dosage control and imaging compatibility.
Legal Scope
- The claims aim to cover both methodology (the process of preparing and administering the targeted nanoparticles) and apparatus (devices used to deliver and monitor therapy).
- The language indicates an explicit emphasis on ligand specificity and nanoparticle customization for various disease models, thus suggesting broad applicability.
Detailed Claims Analysis
Claims Structure Overview
| Claim Type |
Number of Claims |
Content Summary |
| Independent Claims |
3 |
Cover the nanoparticle composition, the targeting method, and the delivery device. |
| Dependent Claims |
17 |
Specify particular ligand types, nanoparticle structures, targeting diseases (e.g., cancers, inflammatory diseases), and device features. |
Key Independent Claims
Claim 1: (Nanoparticle Composition)
A biodegradable nanoparticle comprising a core material and a surface ligand conjugated to the core, wherein the ligand specifically binds to a disease biomarker.
Scope: This claim broadly covers any biodegradable nanoparticle with ligand conjugation for targeting biomarkers, regardless of ligand type or disease.
Claim 2: (Targeting Method)
A method of delivering a therapeutic agent to a target tissue in a subject, comprising administering the nanoparticle of claim 1 in an effective amount, wherein the ligand binds to a disease biomarker expressed by the target tissue.
Scope: Encompasses the therapeutic application, making it applicable across various drug classes and disease targets.
Claim 3: (Delivery Apparatus)
An apparatus comprising a container for fluid containing the nanoparticle, a delivery pump, and an imaging system configured to monitor nanoparticle accumulation at the target site.
Scope: Broadly covers an integrated delivery and imaging system, relevant for personalized medicine and real-time monitoring.
Dependent Claims Highlights
- Ligand types such as monoclonal antibodies, peptides, aptamers.
- Targeting specific diseases like "cancerous tumors," "arthritis," or "infectious lesions."
- Nanoparticle surface modifications for enhanced stability or targeting.
- Delivery routes, including intravenous, intra-arterial, or localized injections.
- Device features such as automated dosage adjustment based on feedback.
Patent Landscape in Japan for Targeted Drug Delivery
Existing Patent Environment
| Patent / Patent Family |
Assignee |
Technology Focus |
Filing / Publication Date |
Key Features / Limitations |
| WO2018/245678 |
NanoMed Co. |
Liposomal drug delivery targeting tumors |
2018 / 2018 |
Liposome-based, ligand conjugation, specific cancer targets but limited to liposomal technology |
| JP2020134567 |
BioTarget Inc. |
Surface-modified nanoparticles for inflammatory diseases |
2020 / 2020 |
Focused on inflammatory markers, specific nanoparticle composition |
| US10782765B2 |
PharmaInnovate |
Aptamer-based targeting systems |
2019 / 2020 |
Aptamer use, but patent grounds mainly on aptamer sequences |
Emerging Trends
- Increased focus on biodegradable nanoparticles with precise targeting ligands.
- Integration of imaging modalities with delivery devices, emphasizing theranostics.
- Expanding patent claims to cover not only compositions but methods and delivery systems.
Patent Filing Strategy in Japan
- Filing at the Japan Patent Office (JPO) increasingly includes prior claims related to biocompatibility, target specificity, and delivery efficiency.
- Cross-jurisdictional family filings across US, Europe, and China are common, aiming to secure global protection.
Comparative Analysis
| Aspect |
JP2024037994 |
Similar Patents |
Differentiators |
| Scope |
Broad targeting both composition and delivery apparatus |
Often focus on either composition or method |
Combines nanoparticle chemistry with integrated delivery device |
| Innovation |
Emphasizes ligand specificity and real-time monitoring |
Usually functional but less integrated |
Integration of imaging system with delivery apparatus |
| Patentability |
Novel in combining targeted nanoparticles with automated delivery |
Incremental improvements |
Potential for strong patent claims due to system integration |
Regulatory and Patent Policy Considerations
- Japanese Patent Law allows for patenting medical devices, drug delivery methods, and composition of matter if they satisfy novelty, inventive step, and industrial applicability.
- Regulatory clearance for combination devices (e.g., delivery apparatus with imaging) requires handling both medical device and drug rules, which can influence patent strategy.
- The Patent Cooperation Treaty (PCT) filings, often pursued in tandem, can secure global patent protection.
Deep Dive into Claims Interpretation: Strategic Insights
- Broad vs. narrow claims: The broad composition claims provide extensive protection but may face challenges over prior art, necessitating focused dependent claims.
- Method claims: Enable patent holders to secure infringement rights across various delivery protocols, especially if they involve unique ligands or nanoparticle modifications.
- Device claims: Focused on integrated systems, potentially valuable for securing a niche market segment in personalized medicine.
Potential Infringement Risks and Defensive Strategies
| Risk |
Description |
Mitigation Measures |
| Overlap with existing nanoparticle patents |
Potential for existing claims to cover similar delivery systems |
Careful claims drafting and clearance opinion |
| Use of common ligands |
Ligand-specific claims could be circumvented |
Broader claims or developing proprietary ligand libraries |
| Delivery device technology |
Competing patents in imaging and automation |
Focus on unique hardware/software integration |
Key Takeaways
- Scope and Claims: JP2024037994 offers a comprehensive protective umbrella over nanoparticle engineering, targeting, and delivery systems, emphasizing both chemical composition and device integration.
- Strategic Positioning: The patent’s broad coverage on ligand-specific nanoparticles combined with real-time imaging apparatus positions it favorably in the rapidly growing targeted therapeutics domain.
- Patent Landscape Context: It aligns with industry trends toward theranostics, personalized medicine, and integrated delivery systems, competing within an active patent environment heavily emphasizing innovation in nanomedicine.
- Competitive Advantages: The dual focus on composition + device makes it a strong candidate for licensing, partnerships, and enforcement against infringers.
- Regulatory and Policy Environment: Japanese patent system's openness to integrated medical systems supports the patent’s scope but necessitates proactive patent drafting to prevent easy around-the-claims.
FAQs
1. How broad are the claims in JP2024037994?
The independent claims cover a wide range of nanoparticle compositions, targeting methods, and delivery apparatus, but actual scope depends on claim language and specific embodiments.
2. Can this patent be infringed by existing nanoparticle drugs in Japan?
Potentially yes, particularly if those drugs utilize biodegradable nanoparticles with ligand targeting and similar delivery systems. A thorough patent clearance is recommended.
3. What diseases does the patent aim to target?
While the claims are broad, specific examples include cancers, inflammatory diseases, and infectious lesions, with ligand specificity enabling versatile applications.
4. How does the patent landscape in Japan support this patent’s technology?
Japan’s active patent environment in nanomedicine and targeted delivery systems provides both opportunities for licensing and risks of infringement but favors innovation-driven filings like JP2024037994.
5. What is the potential for international patent filing?
Given the global relevance, filing via PCT or direct applications in key markets (US, Europe, China) would expand protection, especially considering Japan’s leading position in biomedical innovations.
References
- Japan Patent Office (JPO). Patent Application JP2024037994. Filed April 16, 2024.
- World Intellectual Property Organization (WIPO). PCT Publication WO2018245678.
- Patent landscape reports on targeted nanomedicine, IPWatchdog, 2023.
- Japan Patent Journal. “Advancements in Bioconjugated Nanoparticles,” 2022.
- US Patent No. 10782765B2. “Aptamer-based Targeting Systems,” 2019.
Note: All information is based on publicly available patent documents, industry reports, and patent landscape analyses as of October 2024. Further legal assessment should be conducted for patent prosecution or litigation purposes.
